DALLAS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- AMN Healthcare, the leader and innovator in total talent solutions for healthcare organizations, announces it has approved near and long-term science-based emissions reduction targets with the Science Based Targets initiative (SBTi), joining over 4,000 companies globally in the pursuit of net zero emissions. This decisive move underscores AMN Healthcare’s dedication to sustainability and proactive measures against climate change.
AMN Healthcare has set near- and long-term goals to significantly reduce greenhouse gas (GHG) emissions across its operations and value chain. With a clear alignment to global efforts like the 2015 Paris Agreement, AMN aims to curb its absolute scope 1, 2, and 3 emissions by 42.8% by 2030, based on a 2022 base year. Looking further ahead, the company is committed to a 90% reduction in these emissions by 2050 with all residual emissions neutralized, ultimately achieving net-zero emissions across its value chain by the same year.
To achieve these goals, AMN Healthcare has launched several key initiatives. An internal carbon pricing strategy has been implemented to purchase Renewable Energy Credits (RECs) to offset electricity usage and reduce Scope 1 emissions. A 1.5°C globally aligned Climate Transition Plan and an internal Environmental Policy are in development to guide the company's efforts. Furthermore, AMN is engaging with high-impact suppliers, incorporating environmental requirements into its Vendor Code of Conduct to bolster the collective effort towards sustainability.
The Science-Based Targets initiative, a collaboration among the Carbon Disclosure Project (CDP), United Nations Global Compact, World Resources Institute (WRI), and World Wide Fund for Nature (WWF), provides a clear pathway for businesses to reduce emissions. This initiative plays a crucial role in guiding AMN Healthcare’s strategies to future-proof growth and aligns with global scientific consensus on climate action.
"We believe that businesses have a vital role in driving down GHG emissions and building a resilient, zero-emissions economy," said Cary Grace, President and CEO of AMN Healthcare. "Our commitments not only align with scientific standards but also demonstrate our leadership and responsibility towards a sustainable future."
As AMN Healthcare embarks on this pivotal journey, it emphasizes transparency and accountability. The company is committed to regularly reporting its progress through annual Sustainability & Social Impact Reports and other publicly accessible documents.
For more information about AMN Healthcare's sustainability initiatives, please visit https://www.amnhealthcare.com/about/corporate-social-responsibility/.
About AMN Healthcare
AMN Healthcare is the leader and innovator in total talent solutions for healthcare organizations across the United States. Through a steadfast partnership approach, we solve the most pressing workforce challenges to enable better clinical outcomes and access to care. We provide a comprehensive network of quality healthcare professionals and deliver a fully integrated and customizable suite of workforce technologies.
Media Contact Corporate Communications AMN Healthcare This email address is being protected from spambots. You need JavaScript enabled to view it. | Investor Contact Randle Reece Senior Director, Investor Relations & Strategy AMN Healthcare (866) 861-3229 This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$21.05 |
Daily Change: | -0.63 -2.91 |
Daily Volume: | 617,495 |
Market Cap: | US$801.370M |
June 24, 2025 February 20, 2025 November 07, 2024 August 27, 2024 August 08, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load